Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Amgen | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Amgen

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Amgen

2Q Revenues: $3.6 billion (+14%)

2Q Earnings: $14 million (earnings were $1 billion in 2Q2005)*

YTD Revenues: $6.8 billion (+13%)

YTD Earnings: $1 billion (-46%)

Comments: Worldwide sales of Aranesp increased 26% to $1 billion and combined sales of Neulasta and Neupogen increased 12% to $1 billion in the quarter. North America sales of Enbrel increased 13% to $724 million. Sales of Epogen were down 5% to $613 million. R&D expenses increased 29% to $729 million in the quarter.

*Earnings for the quarter and YTD reflect acquired in-process R&D of $1.1 billion related to the acquisition of Abgenix.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters